Updated Jul 16, 2026
Rowland Charles A Jr is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $2.13M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-09 | GBIO | Generation Bio Co. | J — Other acquisition / disposition | 53.5K | — | |
| 2026-01-06 | VKTX | Viking Therapeutics, Inc. | A — Grant or award | 3.1K | $0.00 | |
| 2025-10-28 | VKTX | Viking Therapeutics, Inc. | S — Open-market sale | 60.0K | $35.57 | $2.13M |
| 2025-10-28 | VKTX | Viking Therapeutics, Inc. | A — Grant or award | 22.0K | $4.88 | $107K |
| 2025-10-28 | VKTX | Viking Therapeutics, Inc. | A — Grant or award | 22.0K | $5.80 | $128K |
| 2025-10-28 | VKTX | Viking Therapeutics, Inc. | A — Grant or award | 16.0K | $4.48 | $72K |
Rowland Charles A Jr is a corporate insider — currently tracked as Director. InsiderAlpha tracks every SEC Form 4 filing in real time.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($2.13M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Rowland Charles A Jr profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.